Trials / Conditions / Orthomyxoviridae Infections

Orthomyxoviridae Infections

20 registered clinical trials studyying Orthomyxoviridae Infections — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challe NCT07215871	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine i NCT05422326	Seqirus	Phase 2
Completed	Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2 NCT03392207	Butantan Institute	—
Completed	Centralized Reminder Recall - Flu RCT2 NCT03294473	University of California, Los Angeles	N/A
Completed	DNA-based Influenza Vaccine in the Elderly NCT01587131	University of Manitoba	Phase 1
Unknown	Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients NCT01055990	Shanghai Public Health Clinical Center	Phase 2
Completed	Safety of H1N1 Influenza Vaccination in Pregnant Women NCT01842997	Jiangsu Province Centers for Disease Control and Prevention	Phase 4
Completed	Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older NCT00975572	Jiangsu Province Centers for Disease Control and Prevention	Phase 2
Completed	Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in C NCT00884182	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzo NCT00755274	Sanofi Pasteur, a Sanofi Company	Phase 4
Completed	Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Fo NCT00718146	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vacc NCT00664417	Sanofi	Phase 1
Completed	Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects NCT00606359	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in A NCT00545701	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine NCT00491257	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children NCT00491985	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy NCT00457509	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine NCT00343681	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly NCT00415129	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Immunogenicity Study of the Influenza Vaccine in Adults NCT00258934	Sanofi Pasteur, a Sanofi Company	Phase 2